GlassScriptPhysician profile
Margaret Gore
NPI 1477551380
$13,395.25
in general payments reported to CMS, 2019-2025
66 companies · $2,843 in 2025
The $2,843 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,054 · 2020: $641 · 2021: $221 · 2022: $2,292 · 2023: $2,693 · 2024: $2,651 · 2025: $2,843.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,948 · Education: $238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,948.38 |
| Education | $237.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $978.86 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $884.16 | 2019-2025 | Keytruda, Welireg, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $869.63 | 2019-2025 | Opdivo, Augtyro, Opdualag |
| Novartis Pharmaceuticals Corporation | $850.88 | 2019-2025 | |
| Abbvie INC. | $627.28 | 2019-2025 | |
| Janssen Biotech, INC. | $516.38 | 2019-2025 | Rybrevant, Darzalex, Tecvayli |
| Daiichi Sankyo INC. | $506.31 | 2019-2025 | Enhertu, Injectafer |
| Incyte Corporation | $470.98 | 2019-2025 | Monjuvi, Pemazyre, Zynyz |
| Astrazeneca Pharmaceuticals LP | $445.08 | 2019-2025 | Enhertu, Imfinzi |
| Seagen INC. | $416.15 | 2019-2023 | Tukysa, Adcetris, Tivdak |
| Takeda Pharmaceuticals U.S.A., INC. | $414.77 | 2019-2025 | Ninlaro, Iclusig |
| Rigel Pharmaceuticals, INC. | $409.96 | 2020-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Lilly USA, LLC | $407.85 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Amgen INC. | $400.80 | 2019-2023 | Lumakras |
| Gilead Sciences, INC. | $384.22 | 2021-2025 | Trodelvy |
Show all 66 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $357.31 | 2020-2025 | Jemperli, Zejula |
| Celgene Corporation | $331.76 | 2019-2024 | Pomalyst, Reblozyl, Opdualag |
| Puma Biotechnology, INC. | $300.92 | 2019-2025 | |
| Genentech USA, INC. | $261.30 | 2019-2025 | Phesgo, Polivy, Perjeta |
| Astellas Pharma US INC | $249.37 | 2019-2025 | Padcev, Xtandi |
| Tesaro, INC. | $216.68 | 2019 | |
| Emd Serono, INC. | $204.21 | 2022-2025 | Bavencio, Tepmetko |
| Genzyme Corporation | $202.87 | 2019-2025 | |
| Eisai INC. | $197.56 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $184.06 | 2022-2025 | Libtayo |
| Exelixis INC. | $149.66 | 2019-2025 | Cabometyx |
| Bayer Healthcare Pharmaceuticals INC. | $148.76 | 2019-2025 | |
| Tempus Ai, INC | $143.10 | 2024-2025 | Xt Cdx |
| Morphosys, US INC. | $131.69 | 2022-2023 | Monjuvi |
| Portola Pharmaceuticals, LLC | $131.49 | 2019 | |
| Genmab U.S., INC. | $114.94 | 2023-2025 | Epkinly |
| Beigene USA, INC. | $104.26 | 2020-2024 | Brukinsa |
| Aveo Pharmaceuticals, INC. | $95.92 | 2023-2025 | Fotivda |
| Servier Pharmaceuticals LLC | $90.79 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $76.27 | 2020-2025 | Ultomiris |
| Sun Pharmaceutical Industries INC. | $68.68 | 2024-2025 | |
| Legend Biotech USA INC. | $64.37 | 2025 | Carvykti |
| Mirati Therapeutics, INC. | $63.55 | 2023-2024 | Krazati |
| Jazz Pharmaceuticals INC. | $60.97 | 2025 | |
| Taiho Oncology, INC. | $58.51 | 2022-2025 | |
| Tersera Therapeutics LLC | $55.53 | 2024-2025 | Zoladex |
| Array Biopharma INC | $55.00 | 2019-2025 | Braftovi, Mektovi, Tukysa |
| Kite Pharma, INC. | $53.15 | 2022-2024 | Yescarta |
| Coherus Oncology, INC. | $51.49 | 2020 | |
| Pharmaessentia USA Corporation | $48.54 | 2025 | Besremi |
| Novocure INC. | $47.15 | 2025 | Optune Lua (Novottf-200t) |
| Sobi, INC | $40.35 | 2024-2025 | |
| Stemline Therapeutics INC. | $36.00 | 2024-2025 | Orserdu |
| Pharmacosmos Therapeutics INC. | $35.07 | 2025 | Monoferric |
| Pharmacyclics LLC, An Abbvie Company | $34.65 | 2022 | |
| Karyopharm Therapeutics INC. | $34.37 | 2024 | Xpovio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.14 | 2020-2024 | |
| Blueprint Medicines Corporation | $28.99 | 2022-2023 | Ayvakit |
| Accord Healthcare, INC. | $28.64 | 2025 | |
| Foundation Medicine, INC. | $28.36 | 2019-2023 | |
| Azurity Pharmaceuticals, INC. | $26.25 | 2025 | Danziten |
| Beone Medicines USA, INC. | $25.81 | 2025 | Brukinsa |
| Secura Bio, INC. | $23.60 | 2019 | |
| Cti Biopharma Corp. | $23.05 | 2023 | Vonjo |
| Apellis Pharmaceuticals, INC. | $18.10 | 2023 | Empaveli |
| Teva Pharmaceuticals USA, INC. | $16.87 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $16.58 | 2025 | Onivyde |
| Myriad Genetic Laboratories, INC. | $14.44 | 2025 | Myrisk |
| Ferring Pharmaceuticals INC. | $14.43 | 2024 | Adstiladrin |
| Kyowa Kirin, INC. | $12.05 | 2022 | |
| Heron Therapeutics, INC. | $2.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Margaret Gore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.